GALAPAGOS NV/S (NASDAQ:GLPG) Lowered to Market Perform at Raymond James

Raymond James downgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a strong-buy rating to a market perform rating in a research note issued to investors on Monday, The Fly reports.

A number of other research analysts have also issued reports on the company. Cantor Fitzgerald reiterated a buy rating and issued a $25.00 target price on shares of Menlo Therapeutics in a report on Thursday, May 2nd. HC Wainwright set a $28.00 target price on Denali Therapeutics and gave the company a buy rating in a report on Monday. Credit Suisse Group started coverage on LTC Properties in a report on Wednesday, July 10th. They issued an underperform rating and a $19.00 target price for the company. Morgan Stanley lifted their target price on Thomson Reuters from $66.00 to $67.00 and gave the company an overweight rating in a report on Monday, April 29th. Finally, BidaskClub downgraded Weyco Group from a sell rating to a strong sell rating in a report on Saturday, July 13th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $148.10.

NASDAQ:GLPG opened at $169.88 on Monday. The stock has a market capitalization of $8.80 billion, a price-to-earnings ratio of -257.39 and a beta of 1.54. The company has a fifty day moving average of $129.46. GALAPAGOS NV/S has a 12-month low of $85.00 and a 12-month high of $174.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.31.

GALAPAGOS NV/S (NASDAQ:GLPG) last released its earnings results on Friday, April 26th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.19) by $0.18. The firm had revenue of $46.47 million during the quarter, compared to analyst estimates of $44.92 million. GALAPAGOS NV/S had a negative return on equity of 3.60% and a negative net margin of 13.24%. Equities analysts anticipate that GALAPAGOS NV/S will post -4.44 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC boosted its position in GALAPAGOS NV/S by 35.3% in the 1st quarter. FMR LLC now owns 502,193 shares of the biotechnology company’s stock valued at $59,148,000 after buying an additional 131,119 shares during the last quarter. Marshall Wace North America L.P. lifted its position in shares of GALAPAGOS NV/S by 149.4% during the first quarter. Marshall Wace North America L.P. now owns 18,751 shares of the biotechnology company’s stock worth $2,208,000 after purchasing an additional 11,233 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of GALAPAGOS NV/S by 121.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 6,200 shares of the biotechnology company’s stock worth $632,000 after purchasing an additional 3,400 shares during the last quarter. Pinnacle Associates Ltd. bought a new position in shares of GALAPAGOS NV/S during the first quarter worth about $231,000. Finally, Stevens Capital Management LP bought a new position in shares of GALAPAGOS NV/S during the first quarter worth about $398,000. 16.32% of the stock is owned by institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Article: How to read a candlestick chart

The Fly

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.